| 翻訳と辞書 |
| Isavuconazole ： ウィキペディア英語版 |
Isavuconazole
Isavuconazole (BAL4815; trade name Cresemba) is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U.S. Food and Drug Administration (FDA) on March 6, 2015〔()〕
During its Phase III drug trials, Astellas partnered with Basilea Pharmaceutica, the developer of the drug, for rights to co-development and marketing of isavuconazole. 〔Saboo, Alok. "Basilea Announces Global Partnership With Astellas for Its Antifungal Isavuconazole." FierceBiotech. N.p., 24 Feb. 2010. Web.〕
On May 28, 2013, Basilea Pharmaceutica announced it had been granted orphan drug status by the FDA for treatment of aspergillosis.〔"Basilea reports isavuconazole orphan drug designation by U.S. FDA." Market Wired. 28 May 2013.〕 Since then, it has also been granted orphan drug status for the treatment of invasive candidiasis.〔"FDA Grants Orphan Drug Designation to Astellas for Isavuconazole for the Treatment of Invasive Candidiasis." News Releases. Astellas. 3 Nov 2014.〕
==Mechanism of action==
Isavuconazole works by inhibiting lanosterol 14 alpha-demethylase, the enzyme responsible for converting lanosterol to ergosterol by demethylation. The resulting depletion of ergosterol and build up of lanosterol compromise the structure of the fungal cell membrane. Mammalian cells are resistant to demethylation inhibition by azoles, making the drug effects specific to fungi.〔Cresemba (isovuconazole sulfate) (information ). Astella Pharma US, Inc. Revised March 2015.〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Isavuconazole」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|